

January 31, 2024

Re: Proposed clinical prior authorization criteria for hepatitis C direct-acting antivirals (DAAs)

The National Viral Hepatitis Roundtable (NVHR) appreciates the opportunity to submit comments on the proposed clinical criteria for the treatment of hepatitis C virus (HCV) for Iowa Medicaid beneficiaries. NVHR is a coalition of patients, health care providers, community-based organizations, and public health partners fighting for an equitable world free of viral hepatitis. In partnership with Harvard Law School's Center for Health Law and Policy Innovation, NVHR tracks and documents HCV treatment access across the country through our Hepatitis C: State of Medicaid Access project ([stateofhepc.org](http://stateofhepc.org)). We routinely publish [national snapshots](#) examining state-level trends in aligning treatment access through state Medicaid programs with evidence-based treatment guidelines.

We commend the Drug Utilization Review Committee for steps taken to improve access to hepatitis C treatment. However, we remain concerned that current criteria violates the Americans with Disabilities Act (ADA) and that progress to date is insufficient to reduce morbidity and mortality associated with a preventable disease. We offer the following recommendations:

#### **Remove criteria related to substance use disorder**

As of August 2023, Iowa was one of only ten state Medicaid programs whose prior authorization process requires that providers document counseling patients about substance use prior to treatment. Although well-intended, in practice, the inclusion of this criteria invites the opportunity for discrimination against people who use substances due to non-evidenced based assumptions about non-adherence. The Department of Justice and the Department of Health and Human Services recently issued a [joint letter](#) (enclosed) informing state Medicaid administrators that, in accordance with the ADA, Medicaid programs must not discriminate against individuals with substance use disorder. DOJ and HHS "urge all state Medicaid administrators to review their current and forthcoming policies, including those on HCV treatment, to determine if any changes are necessary to comply with the ADA." While NVHR shares the goal of improving comprehensive care for people with substance use disorders, our position is that such screening and counseling requirements nevertheless pose undue barriers to accessing appropriate HCV treatment. As such, their inclusion in Medicaid prior authorization criteria for HCV DAAs has not been demonstrated to increase quality nor comprehensiveness of care nor improve patient outcomes. As such, Iowa should remove substance use-related criteria for both initial treatment and retreatment.

#### **Remove criteria related to adherence**

Furthermore, adherence criteria, including the use of psychosocial readiness tools, have not been associated with improved adherence or patient outcomes.<sup>1</sup> While *some* adherence is required for cure, real-world investigations support that even with imperfect adherence, individuals can achieve high

---

<sup>1</sup> Bosch-Capblanch X, Abba K, Prictor M, Garner P. Contracts between patients and healthcare practitioners for improving patients' adherence to treatment, prevention and health promotion activities. Cochrane Database Syst Rev. 2007;(2):CD004808. doi(2):CD004808. doi: 10.1002/14651858.CD004808.pub3 [doi]

rates of sustained virologic response.<sup>2,3</sup> The assessment of readiness and adherence once again creates the possibility for discrimination; poorly validated adherence assessments disproportionately affect marginalized communities such as people who use drugs, despite evidence that these communities successfully complete HCV treatment. While we support voluntary self-assessment of adherence as a tool to identify and address barriers, adherence should not be reflected in the prior authorization process. As such, Iowa should remove criteria related to adherence and readiness.

### Remove prescriber restrictions

We also encourage the DUR to review and revise HCV DAA prior authorization requirements stipulating that HCV treatment be provided by designated specialists. As with sobriety restrictions, state Medicaid programs have trended towards reconsidering and removing these requirements, recognizing that a broader range of health care providers has sufficient capability of managing HCV treatment and will be necessary to achieve population health goals of viral hepatitis elimination, particularly in areas experiencing shortages in specialists. Fortunately, prescribing HCV treatment for non-cirrhotic and compensated cirrhotic patients has been made easy with the adoption of the American Association for the Study of Liver Disease and the Infectious Disease Society of America (AASLD/IDSA) Simplified Treatment Algorithm. This systematic process walks prescribers step-by-step through evidence-based eligibility criteria, pretreatment assessments, and recommended regimens. The simplicity of the guidelines and pan-genotypic nature of preferred agents makes prior authorizations administratively burdensome and obsolete. A study in Rhode Island found that the complete prior authorization process from prescription to DAA acquisition took 45-120 minutes per patient, longer with a protracted denial and appeals process.<sup>4</sup> **Ultimately NVHR encourages Iowa to follow in the footsteps of the 26 state Medicaid programs who have removed prior authorizations for most patients.**

We look forward to the prospect of Iowa making significant progress towards viral hepatitis elimination goals through these policy changes and will monitor developments with great interest.

Sincerely,

Daniel Raymond  
Director of Policy, National Viral Hepatitis Roundtable

Adrienne Simmons, PharmD, MS, BCPS, AAHIVP  
Director of Programs, National Viral Hepatitis Roundtable

---

<sup>2</sup> Rosenthal ES, Silk R, Mathur P, et al. Concurrent initiation of hepatitis C and opioid use disorder treatment in people who inject drugs. *Clin Infect Dis*. 2020;71(7):1715-1722. doi: 10.1093/cid/ciaa105 [doi].

<sup>3</sup> Norton BL, Akiyama MJ, Agyemang L, Heo M, Pericot-Valverde I, Litwin AH. Low adherence achieves high HCV cure rates among people who inject drugs treated with direct-acting antiviral agents. *Open Forum Infect Dis*. 2020;7(10):ofaa377. doi: 10.1093/ofid/ofaa377 [doi].

<sup>4</sup> Duryea P, Habchi J, Sprecht-Walsh S, Thomas AM, Bratberg J, et.al. A Modifiable Barrier to Hepatitis C Virus Elimination in Rhode Island: The Prior Authorization Process for Direct-Acting Antiviral Agents. *R I Med J*. 2020;103(5):41-44. <http://rimed.org/rimedicaljournal/2020/06/2020-06-41-hcv-duryea.pdf>.